# Human MOTS-c peptide blood measurements

> Human blood findings for MOTS-c peptide — Human MOTS-c peptide findings concern blood measurements in obesity, dialysis and multiple sclerosis, plus genetic associations. No treatment trial is implied.

**Human observations**

A blood level carries the circumstances of the person it came from. Childhood obesity and chronic dialysis ask very different questions of the same measurement.

## Children and insulin resistance

Du and colleagues reported [lower circulating MOTS-c in boys with obesity](https://pubmed.ncbi.nlm.nih.gov/29691953/), including male children and adolescents, and an association with insulin resistance. The study measured the peptide already present in the participants’ blood.

Turning “lower” into an instruction to raise a number would skip the causal question: what produced that measurement? The finding gives a relationship to investigate in that population. It does not establish a healthy target range, explain every cause of the lower measurement or demonstrate that giving MOTS-c would improve insulin sensitivity in children.

## Dialysis and cardiovascular risk

The [multicentre chronic-hemodialysis cohort](https://pubmed.ncbi.nlm.nih.gov/39111290/) followed 94 people for a median of 26.5 months. Circulating MOTS-c was independently associated with a combined outcome of all-cause mortality and non-fatal cardiovascular events. The researchers measured endogenous MOTS-c; it was an observational study.

Adding MOTS-c to the risk model increased its area under the ROC curve, or AUC, from 0.727 to 0.743. AUC summarises discrimination: how well the model separates people who later had the outcome from those who did not. Those figures describe prediction, rather than the chance that a treatment succeeds.

My reaction to the modest change is restrained. A blood measurement can have a statistically reported association while adding relatively little discrimination to a model. The study leaves the effect of administering MOTS-c completely unanswered.

![Two bars compare risk-model AUC of 0.727 and 0.743 after adding circulating MOTS-c](images/dialysis-risk-model.svg)

*Risk discrimination in the 94-person dialysis cohort. AUC rose from 0.727 to 0.743; nobody received MOTS-c as study treatment.*

## Genetics, longevity and multiple sclerosis

The [2021 genetics study](https://pubmed.ncbi.nlm.nih.gov/33468709/) linked a sequence-altering mitochondrial DNA variant with type 2 diabetes risk in certain populations. It suggests that inherited differences deserve attention when discussing MOTS-c biology. It supplies no evidence that taking the peptide caused that risk.

An [earlier commentary on exceptional longevity](https://pubmed.ncbi.nlm.nih.gov/26289118/) explored a possible genetic connection with very long life. The longevity genetics intrigue me; a treatment outcome is still missing. The paper’s question is a much narrower proposition than a general claim of life extension.

The [multiple-sclerosis comparison](https://pubmed.ncbi.nlm.nih.gov/35989823/) found different serum MOTS-c levels in patients and healthy controls. Again, disease context entered the measurement. The participants were being compared by existing blood levels, without a MOTS-c treatment intervention.

## The human experiment still missing

Across this evidence base, human work primarily measures a peptide the body already makes. The [review of stress, metabolism and ageing](https://pubmed.ncbi.nlm.nih.gov/36670507/) connects those observations with the cell and animal experiments. Completed human trials demonstrating the efficacy of added MOTS-c are absent.

A carefully monitored human intervention could answer whether changing exposure produces a useful outcome, and what harms accompany it. For now, the human measurements offer clues about physiology and disease. I’m unwilling to build a treatment story out of a blood comparison alone.

The [safety and half-life page](/dosage) covers the other missing measurements. The [questions page](/faq) addresses personal reports, timing and combinations.

---

An exhibition-wall reading of the mitochondrial-derived MOTS-c peptide literature — each study hung as its own plate and cited, the large search demand held apart from the empty human-trial wall, and prescribing access held apart from FDA drug approval; no clinic curates this room and nothing here is dispensed or sold.